Pfizer Inc. on Wednesday announced two strategic appointments in the leadership of the Worldwide Research and Development organization.
Michael Ehlers was selected as group senior vice president and head of BioTherapeutics Research and Development and site head for Pfizer’s Boston and Cambridge, Massachusetts, locations. Ehlers will report to Mikael Dolsten, president of Worldwide Research & Development.
“It’s a privilege to see extraordinary scientific talent rise to the opportunity to grow within our organization and lead the future of Pfizer’s key R&D areas,” Dolsten said. “Mike is a world-class talent who has made significant contributions in advancing our neuroscience research efforts and is now poised to lead BioTherapeutics Research & Development into the next era of potential breakthroughs for patients, not only in neuroscience and pain, but in rare diseases, and also at Pfizer’s Centers for Therapeutic Innovation.”
John Lin was selected as senior vice president and chief scientific officer of Rinat. Lin will report to Robert Abraham, group senior vice president for Oncology-Rinat Research and Development.
“John’s expertise in advancing differentiated antibody programs in both oncology and non-oncology indications is at the core of Rinat’s proven track record of bringing potential therapies such as tanezumab, ponezumab and bococizumab into the clinic,” Abraham said.
Alerts Sign-up